Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
2000-08-15
Burke, Julie
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241361, 4241531, 4241731, 4241751, 5303873, 5303887, 53038885, 5303889, 5303896, 5303891, 5303898, A61K 39395, C07K 1618, C07K 1628, C07K 1644
Patent
active
061032336
ABSTRACT:
First and second compounds are provided, where the first compound is administered to a mammalian host into blood for covalent bonding to blood components, where the components have an extended lifetime in the blood stream. The first compound comprises an active functionality and an agent of interest or a first binding entity. A second compound may be subsequently administered to the patient, which comprises a second binding entity, complementary to the first binding entity and an agent of interest. By virtue of binding to long-lived blood components, the half-life of the agent of interest is greatly extended in vivo.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5843440 (1998-12-01), Pouletty et al.
Christian, J. et al; Senescence of Canine Biotinylated Erythrocytes: Increased Autologous Immunoglobulin Binding Occurs on Erythrocytes Aged In Vivo for 104 to 110 Days, Blood, vol. 82, No. 11, pp. 3469-3473 (1993).
Coller, B. et al, Thromboerythrocytes, J. Clin. Invest. vol. 89, pp. 546-555, (1992).
Gilles, S. et al; Antigen biding and biological activities of engineered mutant chimeric antibodies with human tumor specificities; Hum. Antibod. Hybridomas vol. 1, No. 1 pp. 47-54 (1990).
Harris, W. et al; Therapeutic antibodies--the coming of age; Btech, vol. 11 (1993).
Kinsey, B. et al; Efficient Conjugation of DTPA to an IgM Monoclonal Antibody in Ascites Fluid; Nucl. Med. Biol. vol. 15 No. 3 pp. 285-292 (1988).
Lambert, J. et al; Purified Immunotoxins that are Reactive with Human Lymphoid Cells, Journal of Bilogical Chemistry, vol. 260, No. 22, pp. 12035-122041 (1985).
Kurantsin-Mills, J. et al; Indium-111 Oxine Labeled Erythrocytes: Cellular Distribution and Efflux Kinetics of the Label, Nucl. Med. Biol. vol. 16, No. 8, pp. 821-827 (1989).
Magnani, M. et al; Preparation and characterization of biotinylated red blood cells, Biotechnol. Appl. Biochem, vol 20, pp. 335-345, (1990).
Magnani, M. et al; Red Blood Cells as an Antigen-Delivery System; Biotechnol. Appl. Biochem, vol. 16, pp. 188-194 (1992).
Proulx, A. et al; A Kit for Labelling Erthrocytes or Leukocytes with Technitium-99m, Nucl. Med. Biol. vol. 17, No. 5, pp. 515-517 (1990).
Samokhin, G. et al; Red blood cell targeting to collagen-coated surfaces, Febs Letters, vol. 154, No. 2, pp. 257-261 (1983).
Schlom, J. Monoclonal Antibodies: They're More and Less Than You Think; Molecular Foundations on Oncology, pp. 95-134, (1991).
Suzuki, T. et al; Biotinylated Erythrocytes: In Vivo Survival and In Vitro Recovery, Blood. vol. 70, No. 3, pp. 791-795 (1987).
Taylor, R. et al. In Vivo Binding and Clearance of Circulating Antigen by Bispecific heteropolymer-Mediated Binding to Primate Erythrocyte Complement Receptor, Journal of Immunology, vol. 148, No. 8, pp. 2462-2468 (1992).
Taylor, R. et al; Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human, erythrocytes: A potential therapeutic treatment, Proc. Natl. Acad. Sci, USA, vol. 88, pp. 3305-3309 (1991).
Coller, Barry S., et al: Thromboerythrocytes In Vitro Studies of a Potential Autologous, Semi-artifical Alternative to Platelet Transfusions, J. Clin. Invest. vol. 89, pp. 546-555 (1992).
Kinsey, BM. et al. 1988. Nucl. Med. Biol. 15: 285-292 Christian, JA. et al. 1993, Blood 82:3469-3473.
Y. Collet, B. et al. Cancer Immunol. Immunother, 26:237-242, 1988.
Pouletty Christine
Pouletty Philippe
Burke Julie
ConjuChem Inc.
LandOfFree
Cellular and serum protein anchors and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cellular and serum protein anchors and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cellular and serum protein anchors and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2003721